Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Eli Lilly struck a deal Tuesday to develop ...
Eli Lilly has entered a research collaboration worth up to $2.25 billion with AI biotech Profluent to develop custom enzymes for advanced genetic medicines. The deal gives Lilly exclusive rights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results